期刊
EUROPEAN JOURNAL OF CANCER
卷 48, 期 3, 页码 377-384出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2011.10.016
关键词
Non-small cell lung cancer; Brain metastases; Gefitinib; Temozolomide; Whole brain radiotherapy; Quality of life; Cognitive function
类别
资金
- Essex Chemie, Switzerland
- AstraZeneca (Switzerland)
- Swiss State Secretariat for Education and Research (SER)
Purpose: Patients with brain metastases (BM) rarely survive longer than 6 months and are commonly excluded from clinical trials. We explored two combined modality regimens with novel agents with single agent activity and radiosensitizing properties. Patients and methods: In this randomised phase II trial patients with BM from NSCLC were randomly assigned to 30 Gy WBRT with either concomitant gefitinib (GFT) 250 mg/day continuously or temozolomide (TMZ) 75 mg/m(2) for 21/28 days. The primary end-point was overall survival, with quality of life and cognitive function as secondary end-points. Results: We enrolled 59 patients (GFT 16, TMZ 43), and 56 patients have died, mainly (80%) from disease progression. Four patients succumbed complications of the disease or corticosteroids (intestinal perforation (2), CNS haemorrhage and pulmonary emboli). Median overall survival in the gefitinib arm was 6.3 months (95% CI 2.1-14.6), and 4.9 months (95% CI 2.3-5.6) in TMZ treated patients. Fatigue was the main complaint. Conclusions: No relevant toxicity with those therapeutic regimens was observed. Fatal outcome in three patients may have been related to corticosteroids. Cognitive function improved during treatment. However, median overall survival for all patients was only 4.9 months (95% CI 2.3-5.7) and 1-year survival 25.4% (95% CI 15.4-37.0%). (C) 2011 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据